Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 4, 2009, Pages 1353-1361

  Clark, Catherine ^a   Ednie, Lois M ^a   Lin, Gengrong ^a   Smith, Kathy ^a   Kosowska Shick, Klaudia ^a   McGhee, Pamela ^a   Dewasse, Bonifacio ^a   Beachel, Linda ^a   Caspers, Patrick ^b   Gaucher, Bérangère ^b   Mert, Gürkan ^a   Shapiro, Stuart ^b   Appelbaum, Peter C ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b BASILEA PHARMACEUTICA INTERNATIONAL LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BAL 0030543; BAL 0030544; BAL 0030545; CLINDAMYCIN; LINEZOLID; MINOCYCLINE; PHTHALAZINE DERIVATIVE; RIFAMPICIN; TRIMETHOPRIM; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; FOLIC ACID ANTAGONISTS; MICROBIAL SENSITIVITY TESTS; PHTHALAZINES; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 65649084152     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01619-08     Document Type: Article

References (41)

1. Almeida, R. A., and S. P. Oliver. 2001. Interaction of coagulase-negative Staphylococcus species with bovine mammary epithelial cells. Microb. Pathog. 31:205-212. (Pubitemid 33096065)
2. Appelbaum, P. C. 2007. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Int. J. Antimicrob. Agents 30:398-408. (Pubitemid 47498971)
3. Asbell, P. A., K. A. Colby, S. Deng, P. McDonnell, D. M. Meisler, M. B. Raizman, J. D. Sheppard, Jr., and D. F. Sahm. 2008. Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates. Am. J. Ophthalmol. 145:951-958.
4. Beekmann, S. E., D. N. Gilbert, P. M. Polgreen, and the IDSA Emerging Infections Network. 2008. Toxicity of extended courses of linezolid: results of an Infectious Diseases Society of America Emerging Infections Network survey. Diagn. Microbiol. Infect. Dis. 62:407-410.
5. Binda, G., E. Domenichini, A. Gottardi, B. Orlandi, E. Ortelli, B. Pacini, and G. Fowst. 1971. Rifampicin, a general review. Arzneimittel-Forschung 21: 1907-1977.
6. Bjorland, J., T. Steinum, B. Kvitle, S. Waage, M. Sunde, and E. Heir. 2005. Widespread distribution of disinfectant resistance genes among staphylococci of bovine and caprine origin in Norway. J. Clin. Microbiol. 43:4363-4368. (Pubitemid 41298214)
7. Boelens, J. J., J. Dankert, J. L. Murk, J. J. Weening, T. van der Poll, K. P. Dingemans, L. Koole, J. D. Laman, and S. A. J. Zaat. 2000. Biomaterial-associated persistence of Staphylococcus epidermidis in pericatheter macrophages. J. Infect. Dis. 181:1337-1349. (Pubitemid 30252538)
8. Bogdanovich, T., L. M. Ednie, S. Shapiro, and P. C. Appelbaum. 2005. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob. Agents Chemother. 49:4210-4219. (Pubitemid 41400966)
9. Bolmström, A., A. Karlsson, and P. Wong. 1999. 'Macro'-method conditions are optimal for detection of low-level glycopeptide resistance in staphylococci. Clin. Microbiol. Infect. S(Suppl. 3):113.
10. Burdeska, A., M. Ott, W. Bannwarth, and R. L. Then. 1990. Identical genes for trimethoprim-resistant dihydrofolate reductase from Staphylococcus aureus in Australia and central Europe. FEBS Lett. 266:159-162. (Pubitemid 20194196)
11. Caspers, P., B. Gaucher, and S. Shapiro. 2007. Dihydrophthalazine antifolates, a family of novel antibacterial drugs: resistance and bactericidal properties towards staphylococci, abstr. Fl-932. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother.
12. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 7th ed.; approved standard. CLSI publication no. M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
13. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing; 18th informational supplement. CLSI publication no. Ml00-S18. Clinical and Laboratory Standards Institute. Wayne, PA.
14. Dale, G. E., R. L. Then, and D. Stiiber. 1993. Characterization of the gene for chromosomal trimethoprim-sensitive dihydrofolate reductase of Staphylococcus aureus ATCC 25923. Antimicrob. Agents Chemother. 37:1400-1405. (Pubitemid 23202360)
15. Del'Alamo, L., R. F. Cereda, I. Tosin, E. A. Miranda, and H. S. Sader. 1999. Antimicrobial susceptibility of coagulase-negative staphylococci and characterization of isolates with reduced susceptibility to glycopeptides. Diagn. Microbiol. Infect. Dis. 34:185-191. (Pubitemid 29287212)
16. de la Torre, M., M. Sanchez, G. Morales, E. Baos, A. Arribi, N. Garcia, R. Andrade, B. Pelaez, M. P. Pacheco, S. Domingo, J. Conesa, M. Nieto, F. J. Candel, and J. Picazo. 2008. Outbreak of linezolid-resistant Staphylococcus aureus in intensive care, abstr. C2-1835a. Program/Abstr. Addendum 48th Intersci. Conf. Antimicrob. Agents Chemother./46th Annu. Meet. Infect. Dis. Soc. Am.
17. Ding, Y., Y. Onodera, J. C. Lee, and D. C. Hooper. 2008. NorB, an efflux pump in Staphylococcus aureus strain MW2, contributes to bacterial fitness in abscesses. J. Bacteriol. 190:7123-7129.
18. Fritsche, T. R., H. S. Sader, and R. N. Jones. 2007. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004). Diagn. Microbiol. Infect. Dis. 58:19-26. (Pubitemid 46694276)
19. Garrett, D. O., E. Jochimsen, K. Murfltt, B. Hill, S. McAllister, P. Nelson, R V. Spera, R. K. Sail, F. C. Tenover, J. Johnston, B. Zimmer, and W. R. Jarvis. 1999. The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis. Infect. Control Hosp. Epidemiol. 20:167-170.
20. Gaucher, B., A. Schmitt-Hofimann, P. Caspers, K. Gebhardt, C. Nuoffer, H. Urwyler, and J. Heim. 2007. Dihydrophthalazine antifolates, a family of novel antibacterial drugs: in vitro and in vivo pharmacological profiles, abstr. Fl-935. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother.
21. Hackbarth, C. J., H. F. Chambers, and M. A. Sande. 1986. Serum bactericidal activity of rifampin in combination with other antimicrobial agents against Staphylococcus aureus. Antimicrob. Agents Chemother. 29:611-613. (Pubitemid 16106381)
22. Johnson, M. D., and C. F. Decker. 2008. Antimicrobial agents in treatment of MRSA infections. Dis. Mon. 54:793-800. (Pubitemid 12083285)
23. Jones, R N., J. E. Ross, M. Castanheira, and R. E. Mendes. 2008. United States resistance surveillance results for linezolid (LEADER Program for 2007). Diagn. Microbiol. Infect. Dis. 62:416-426.
24. Kosowska-Shick, K., K. Julian, J. Kishel, P. McGhee, P. C. Appelbaum, and C. Whitener. 2008. Molecular and epidemiological characteristics of linezolid-resistant coagulase-negative staphylococci at a tertiary-care hospital, abstr. C2-1081. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother.
25. McDougal, L. K., C. D. Steward, G. E. Killgore, J. M. Chaitram, S. K. McAllister, and F. C. Tenover. 2003. Pulsed-field electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J. Clin. Microbiol. 41:5113-5120. (Pubitemid 37429924)
26. Mendes, R. E., L. M. Deshpande, M. Castanheira, J. DiPersio, M. A. Saubolle, and R. N. Jones. 2008. First report of c/ř-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob. Agents Chemother. 52:2244-2246.
27. Merkel, G. J., and B. A. Scofleld. 2001. Interaction of Staphylococcus epidermidis with endothelial cells in vitro. Med. Microbiol. Immunol. 189:217-223. (Pubitemid 32835375)
28. Miller, L. G., F. Perdreau-Remington, G. Rieg, S. Mehdi, J. Perlroth, A. S. Bayer, A. W. Tang, T. O. Phung, and B. Spellberg. 2005. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N. Engl. J. Med. 352:1445-1453. (Pubitemid 40471452)
29. Owens, R. C, Jr. 2008. Antimicrobial stewardship: concepts and strategies in the 21st century. Diagn. Microbiol. Infect. Dis. 61:110-128. (Pubitemid 352844253)
30. Pan, A., S. Lorenzotti, and A. Zoncada. 2008. Registered and investigational drags for the treatment of methicillin-resistant Staphylococcus aureus infection. Recent Pat. Anti-Infect. Drug Discov. 3:10-33.
31. Pankuch, G. A., M. R. Jacobs, and P. C. Appelbaum. 1994. Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, Sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology. Antimicrob. Agents Chemother. 38:2065-2072. (Pubitemid 24278802)
32. Potoski, B. A., J. Adams, L. Clarke, K. Shutt, P. K. Linden, C. Baxter, A. W. Pasculle, B. Capitano, A. Y. Peleg, D. Szabo, and D. L. Paterson. 2006. Epidemiological profile of linezolid-resistant coagulase-negative staphylococci. Clin. Infect. Dis. 43:165-171.
33. Ruef, C. 2004. Epidemiology and clinical impact of glycopeptide resistance in Staphylococcus aureus. Infection 32:315-327. (Pubitemid 40104674)
34. Rybak, M. J., D. M. Cappelletty, T. Moldovan, J. R. Aeschlimann, and G. W. Kaatz. 1998. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium. Antimicrob. Agents Chemother. 42:721-724. (Pubitemid 28114839)
35. Sekiguchi, J.-I., P. Tharavichitkul, T. Miyoshi-Akiyama, V. Chupia, T. Fujino, M. Araake, A. I rie, K. Morita, T. Kuratsuji, and T. Kirikae. 2005. Cloning and characterization of a novel trimethoprim-resistant dihydrofolate reductase from a nosocomial isolate of Staphylococcus aureus CM.S2 (IMCJ1454). Antimicrob. Agents Chemother. 49:3948-3951. (Pubitemid 41233057)
36. Shapiro, S., L. Thenoz, S. Heller, and P. Caspers. 2007. Dihydrophthalazine antifolates, a family of novel antibacterial drugs: in vitro activities against diverse bacterial pathogens, abstr. Fl-933. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. (Pubitemid 47532233)
37. Sutherland, B., and G. N. Rolinson. 1964. Characteristics of methicillin-resistant staphylococci. J. Bacteriol. 87:887-899.
38. Szumowski, J. D., D. E. Cohen, F. Kanaya, and K. H. Mayer. 2007. Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic. Antimicrob. Agents Chemother. 51:423-428. (Pubitemid 46185256)
39. Tenover, F. C, and R C. Moellering, Jr. 2007. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin. Infect. Dis. 44:1208-1215. (Pubitemid 46651246)
40. Venkatesh, M. P., F. Placencia, and L. E. Weisman. 2006. Coagulase-negative staphylococcal infections in the neonate and child: an update. Semin. Pediatr. Infect. Dis. 17:120-127. (Pubitemid 44278616)
41. Veyssier, P., and A. Bryskier. 2005. Dihydrofolate reductase inhibitors, nitroheterocycles (furans), and 8-hydroxyquinolines, p. 941-963. In A. Biyskier (ed.). Antimicrobial agents: antibacterial and antifungals. ASM Press, Washington, DC.